667 related articles for article (PubMed ID: 7693298)
21. Early effects of intrastriatal injections of quinolinic acid on microtubule-associated protein-2 and neuropeptides in rat basal ganglia.
Bordelon YM; Chesselet MF
Neuroscience; 1999; 93(3):843-53. PubMed ID: 10473250
[TBL] [Abstract][Full Text] [Related]
22. Chapter 33: the history of movement disorders.
Lanska DJ
Handb Clin Neurol; 2010; 95():501-46. PubMed ID: 19892136
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of subliminally primed responses is mediated by the caudate and thalamus: evidence from functional MRI and Huntington's disease.
Aron AR; Schlaghecken F; Fletcher PC; Bullmore ET; Eimer M; Barker R; Sahakian BJ; Robbins TW
Brain; 2003 Mar; 126(Pt 3):713-23. PubMed ID: 12566291
[TBL] [Abstract][Full Text] [Related]
24. Deep brain stimulation for Huntington's disease: long-term results of a prospective open-label study.
Gonzalez V; Cif L; Biolsi B; Garcia-Ptacek S; Seychelles A; Sanrey E; Descours I; Coubes C; de Moura AM; Corlobe A; James S; Roujeau T; Coubes P
J Neurosurg; 2014 Jul; 121(1):114-22. PubMed ID: 24702329
[TBL] [Abstract][Full Text] [Related]
25. Regional distribution of methionine-enkephalin and substance P-like immunoreactivity in normal human brain and in Huntington's disease.
Emson PC; Arregui A; Clement-Jones V; Sandberg BE; Rossor M
Brain Res; 1980 Oct; 199(1):147-60. PubMed ID: 6157454
[TBL] [Abstract][Full Text] [Related]
26. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
Perry TL; Hansen S; Kloster M
N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
[No Abstract] [Full Text] [Related]
27. Immunocytochemical studies on the basal ganglia and substantia nigra in Parkinson's disease and Huntington's chorea.
Waters CM; Peck R; Rossor M; Reynolds GP; Hunt SP
Neuroscience; 1988 May; 25(2):419-38. PubMed ID: 2456487
[TBL] [Abstract][Full Text] [Related]
28. Decreased glutamic acid and increased 5-hydroxytryptamine in Huntington's disease brain.
Reynolds GP; Pearson SJ
Neurosci Lett; 1987 Jul; 78(2):233-8. PubMed ID: 2442679
[TBL] [Abstract][Full Text] [Related]
29. Discriminating chorea-acanthocytosis from Huntington's disease with single-case voxel-based morphometry analysis.
Suzuki F; Sato N; Ota M; Sugiyama A; Shigemoto Y; Morimoto E; Kimura Y; Wakasugi N; Takahashi Y; Futamura A; Kawamura M; Ono K; Nakamura M; Sano A; Watanabe M; Matsuda H; Abe O
J Neurol Sci; 2020 Jan; 408():116545. PubMed ID: 31704285
[TBL] [Abstract][Full Text] [Related]
30. The cortical lesion of Huntington's disease: further neurochemical characterization, and reproduction of some of the histological and neurochemical features by N-methyl-D-aspartate lesions of rat cortex.
Storey E; Kowall NW; Finn SF; Mazurek MF; Beal MF
Ann Neurol; 1992 Oct; 32(4):526-34. PubMed ID: 1280937
[TBL] [Abstract][Full Text] [Related]
31. Role of pallidum in genesis of some choreic movements.
SPIEGEL EA; WYCIS HT
Neurology; 1953 Apr; 3(4):261-6. PubMed ID: 13054853
[No Abstract] [Full Text] [Related]
32. Studies on neurotransmitter markers of the basal ganglia in Pick's disease, with special reference to dopamine reduction.
Kanazawa I; Kwak S; Sasaki H; Muramoto O; Mizutani T; Hori A; Nukina N
J Neurol Sci; 1988 Jan; 83(1):63-74. PubMed ID: 2450180
[TBL] [Abstract][Full Text] [Related]
33. Metabolic and electrophysiological changes in the basal ganglia of transgenic Huntington's disease rats.
Vlamings R; Benazzouz A; Chetrit J; Janssen ML; Kozan R; Visser-Vandewalle V; Steinbusch HW; von Hörsten S; Temel Y
Neurobiol Dis; 2012 Dec; 48(3):488-94. PubMed ID: 22813864
[TBL] [Abstract][Full Text] [Related]
34. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
35. Elevation of Met-enkephalin-like immunoreactivity in the rat striatum and globus pallidus following the focal injection of excitotoxins.
Ruzicka BB; Jhamandas K
Brain Res; 1990 Dec; 536(1-2):227-39. PubMed ID: 2150770
[TBL] [Abstract][Full Text] [Related]
36. Distribution and binding parameters of GABAA receptors in the thalamic nuclei of Macaca mulatta and changes caused by lesioning in the globus pallidus and reticular thalamic nucleus.
Ambardekar AV; Surin A; Parts K; Ilinsky IA; Kultas-Ilinsky K
Neuroscience; 2003; 118(4):1033-43. PubMed ID: 12732248
[TBL] [Abstract][Full Text] [Related]
37. Early GABAergic transmission defects in the external globus pallidus and rest/activity rhythm alteration in a mouse model of Huntington's disease.
Du Z; Chazalon M; Bestaven E; Leste-Lasserre T; Baufreton J; Cazalets JR; Cho YH; Garret M
Neuroscience; 2016 Aug; 329():363-79. PubMed ID: 27217211
[TBL] [Abstract][Full Text] [Related]
38. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
39. Mechanisms underlying the enhancement of γ-aminobutyric acid responses in the external globus pallidus of R6/2 Huntington's disease model mice.
Barry J; Sarafian TA; Watson JB; Cepeda C; Levine MS
J Neurosci Res; 2020 Nov; 98(11):2349-2356. PubMed ID: 32856336
[TBL] [Abstract][Full Text] [Related]
40. The globus pallidus as a target for neuropeptides and endocannabinoids participating in central activities.
Chen XY; Xue Y; Chen H; Chen L
Peptides; 2020 Feb; 124():170210. PubMed ID: 31778724
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
